Immunophotonics, Inc.
St. Louis, US · 2 known investors
Immunophotonics is a clinical-stage biotech company developing novel treatments for solid-tumor cancers and infectious diseases by combining tumor ablation with systemic cancer immunotherapy. The company's intellectual property platform includes IP-001, designed to transform routine ablation procedures into systemically active cancer immunotherapy.
BiotechDeep TechDigital HealthMedical Devices
Founders & leadership
DH
Dr. HodeCo-Founder & Senior Fellow
MA
Mr. AlleruzzoCo-Founder & Director
DC
Dr. ChenCo-Founder
DR
Dr. Robert NordquistCo-Founder
Investors · 2
In the news
- St. Louis cancer drug startup Immunophotonics inks research pact with innovation arm of Johnson & Johnson - St. Louis Business Journalbizjournals.com · 2024
- FCOI Policy - Immunophotonicsimmunophotonics.com · 2023
- Immunophotonics Raises $21.4M Series B | Cultivation Capitalcultivationcapital.com · 2022
- Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials - Immunophotonicsimmunophotonics.com · 2022
- Immunophotonics - 2026 Company Profile, Team, Funding & Competitors - Tracxntracxn.com · 2021
- Immunophotonics - 2025 Funding Rounds & List of Investors - Tracxntracxn.com · 2021